ReviewWorld journal of hepatology2015
Hepatitis C virus: Virology, diagnosis and treatment.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- Guideline
- Trial
- Revisiting Anti-HCV Seropositivity: Signal Intensity, Diagnostic Uncertainty, and the Limitations of Fixed Cut-Offs.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy.Health science reports · 2026Article
- Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia.BMC infectious diseases · 2026Article
- The dynamic interplay between viruses and host non-coding RNA species.FEMS microbiology reviews · 2026Review
- A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran.Cost effectiveness and resource allocation : C/E · 2025Article
- Trends in Mortality Caused by Hepatitis C Virus in the United States Population: A Retrospective Cross-Sectional Study Using the CDC WONDER Database.Digestive diseases and sciences · 2025Article
- Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C-A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2025Review
- Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India.Journal of family medicine and primary care · 2025Article
- Determination of the Viremia and Genotype Distribution of the Hepatitis C Virus and the Seroprevalence of HIV Co-Infection.Infectious diseases & clinical microbiology · 2025Article
- Article
- Analysis of the Results of Hepatitis B and C Molecular Tests in Southern Iran from 2018 to 2022, the Possibility of Hepatitis C Genotype Change in the Region.Advanced biomedical research · 2025Article
- Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.Viruses · 2024Review
- Article
- Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications.Molecular therapy. Nucleic acids · 2024Review
- Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations.Frontiers in chemistry · 2024Article
- Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis.International journal of cardiology. Heart & vasculature · 2023Article
- Chronic viral hepatitis accelerates lung function decline in smokers.Clinical and experimental medicine · 2023Article
- Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than twenty years of study has provided a better understanding of hepatitis C virus (HCV) life cycle, including the general properties of viral RNA and proteins. This effort facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict the likelihood of response. In the early 2000s, pegylated interferon plus ribavirin became the standard anti-HCV treatment. However, this therapy is not ideal. To 2014, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration for the treat of HCV infections. It is likely that the new all-oral, interferon-free, pan-genotyping anti-HCV therapy will be available within the next few years. Majority of HCV infections will be cured by these anti-viral treatments. However, not all patients are expected to be cured due to viral resistance and the high cost of antiviral treatments. Thus, an efficient prophylactic vaccine will be the next challenge in the fight against HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.